

Ref: FOI/GS/ID 6913

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

28 October 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of blood disorders.

You asked:

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:

- a. Doptelet (avatrombopag)*
- b. Jakavi (ruxolitinib)*
- c. Nplate (romiplostim)*
- d. Revolade (eltrombopag)*
- e. Tavlesse (fostamatinib)*
- f. Hydroxycarbamide*

Q2. In the last 6 months, how many patients has your trust treated for:

- a. Immune thrombocytopenia (ICD10 code D69.3)*
 - b. Myelofibrosis (ICD10 code D47.4)*
 - c. Myelofibrosis (ICD10 code D47.4) – patients over the age 65*
- Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:*

- a. Mycophenolate mofetil*
- b. Rituximab*
- c. Surgery (splenectomy)*

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- a. Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?*
- b. Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?*

Q5. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Q6. Does your trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Trust response:

Q1.

- a. Not used at MTW
- b. 21
- c. 17
- d. 41
- e. Not used at MTW
- f. 266

Q2. April to September. Please note these patients may have had multiple admission/treatments.

- a. Immune thrombocytopenia (ICD10 code D69.3) From 1 April 2021 to 30 September 2021 52 patients were treated
- b. Myelofibrosis (ICD10 code D47.4) From 1 April 2021 to 30 September 2021 – 9 patients were treated
- c. Myelofibrosis (ICD10 code D47.4) – patients over the age 65 from the total 9 patients a total of 6 patients were aged over 65 years

Q3. We are not able to split diagnosis on pharmacy Data. Exempt under Section 12 of the Act as would require the manual checking of patient records by medical staff.

Q4. We are not able to split diagnosis on pharmacy Data. Exempt under Section 12 of the Act as would require the manual checking of patient records by medical staff.

Q5. None at present.

Q6. One currently in set up.